NIKA · Nika Pharmaceuticals, Inc
$0.41
At close · Aug 26
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 10, 2026
Market Cap
$431.19M
Shares
1.05B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2024
Net Income
-$76.4K
+20.2%
FY2025
Diluted EPS
$0.00
FY2025
Operating Cash Flow
-$79.65K
+48.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | — | $0 | $0 | $0 | $0 | — | — | |
| $54.41K | $53.03K | $35.17K | $64.83K | $33.72K | $14.71K | $8907 | — | |
| $78.13K | $76.4K | $95.79K | $64.83K | $3.18M | $14.71K | $8907 | — | |
| -$78.13K | -$76.4K | -$95.79K | -$64.83K | -$3.18M | -$14.71K | -$8907 | — | |
| -$78.13K | -$76.4K | -$95.79K | -$64.83K | -$3.18M | -$14.71K | -$8907 | — | |
| -$78.13K | -$76.4K | -$95.79K | -$64.83K | -$3.18M | -$14.71K | -$8907 | — | |
| USD/shares | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| USD/shares | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| shares | — | 1.05B | 1.02B | 876.09M | 723.95M | 396.09M | 13.2M | 13.2M |
| shares | — | 1.05B | 1.02B | 876.09M | 723.95M | 396.09M | 13.2M | 13.2M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.92×
EV/EBIT
—
Peer median 18.36×
P/E (TTM)
—
Peer median 13.33×
Peer medians compare against the 48 similar-size Drug Manufacturers - Specialty & Generic companies (of 95 listed).